Back to PFEView Full LandscapeView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
12 competitors in Non-Small Cell Lung Cancer
REGNLibtayo
Phase 3MRKArm A: Pemetrexed Cisplatin
Phase 2SNYoxaliplatine / gemcitabine / Vinorelbine
Phase 2RHHBYerlotinib HCl
Phase 2BNTXBNT327
Phase 2Drug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA4/2/2019
Vizimpro
Vizimpro, as monotherapy, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations.
View on EMADrug Science
Mechanism of action & safety profile
Related Pipeline
13 valent pneumococcal conjugate vaccine with Polysorbate 80Phase 3
Vaccines, Pneumococcal
Insulin LisproPhase 3
Diabetes Mellitus
Cyclosporine APhase 3
Renal Transplantation
DVS-233 SR (desvenlafaxine sustained release )Phase 3
Major Depressive Disorder
MeropenemPhase 3
Complicated Intra-abdominal Infections
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts